Morgan Stanley says 'buy the dip' in Disc Medicine (IRON)
Tweet Send to a Friend
Morgan Stanley analyst Sean Laaman reiterated an Overweight rating and $120.00 price target on Disc Medicine (NASDAQ: IRON) after management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
